3 Drugs Set to Become Blockbusters in 2014

Medivation (MDVN), Gilead (GILD) and Biogen (BIIB) all have new drugs likely to exceed the $1 billion annual sales mark this year.

May 11, 2014 at 11:30AM

Blockbuster status, an unofficial gold medal awarded to therapies racking up sales of $1 billion or more per year, is the holy grail for drug developers. Arguably, it's the chance to discover blockbusters that fuel industry R&D spending and offsets the loss of billions spent working on drugs that end up on the cutting room floor. However, knowing which drugs will become blockbusters isn't easy. Industry watchers often predict big bucks for compounds in development that fail to live up to expectations.

So, instead of guessing which drugs might end up big winners, let's instead consider three recently approved drugs already on the way to becoming blockbusters.

The three include a fast-growing anticoagulant from Johnson & Johnson (NYSE:JNJ) and Bayer (NASDAQOTH:BAYRY), a revolutionary new hepatitis C treatment from Gilead (NASDAQ:GILD), and a new oral drug from multiple sclerosis powerhouse Biogen (NASDAQ:BIIB).

JNJ Chart

JNJ data. Source: YCharts.

1. Johnson & Johnson and Bayer's Xarelto
Patients recovering from post-operative knee and hip surgery and heart disease patients have been prescribed warfarin, or Coumadin, to reduce the chance of stroke for decades. However, warfarin is facing off against a slate of new anticoagulants designed to reduce the risk of brain hemorrhages, eliminate interactions with common foods, and lower the need for inconvenient monitoring. These new drugs include Boehringer's blockbuster Pradaxa, and Pfizer and Bristol-Myers' fast-growing Eliquis. But the most impressive of the new anticoagulants so far has been Johnson and Bayer's Xarelto.

Johnson handles sales of Xarelto in the U.S., and the company recorded sales of $246 million from the drug in the third quarter, $270 million in the fourth quarter, and $319 million in the first quarter, which was double last year's sales. Bayer is responsible for Xarelto overseas and, thanks to EU regulators expanding Xarelto's label to include patients with acute coronary syndrome last summer, Xarelto sales soared from $213 million last year to $471 million in the first quarter.

That impressive growth puts global Xarelto sales on track to challenge $3 billion this year, but they could go even higher if a partnership with Portola pans out. Portola is working with the companies to develop an antidote for Xarelto that would reverse its effects. If they succeed, it could clear the way for Xarelto to be used in more patients, like those most at risk of bleeding events. 

2. Gilead's Sovaldi
Few drugs have been as widely anticipated as Gilead's sofosbuvir, which was named Sovaldi when it won Food and Drug Administration approval as a treatment for hepatitis C in December. Gilead spent more than $11 billion to capture the drug through its acquisition of Pharmasset in 2010 and industry watchers have long speculated on its blockbuster potential given the market for hepatitis C treatment is $20 billion.

Sovaldi expectations were so big that doctors chose to warehouse patients rather than treat them with Vertex's Incivek -- the go-to standard that became the fastest drug to reach blockbuster status when it won FDA approval in 2011. That is, until Sovaldi won approval in December, and went on to post a jaw-dropping $2.3 billion in sales during the first quarter. Sovaldi's success stems from impressive trial results that outperformed its closest competitior, Johnson & Johnson's Olysio, which won FDA approval last November.

During their respective phase 3 trials, Sovaldi cleared hepatitis C in 89% of patients with genotype 1 versus 84% treated with Olysio. That advantage, significant pent-up demand, and a staggering $84,000 price tag created a perfect storm for sales to rocket higher. Looking ahead, Sovaldi has a good shot at becoming the top-selling drug on the planet. Gilead has already filed for FDA approval of a next-generation Sovaldi therapy that combines the drug with Ledipasvir, potentially eliminating side effect-laden interferon and ribavirin from treatment regimens. 

That should help deflect a range of competing hepatitis C treatments making their way through the FDA, including a promising three-drug combination therapy from AbbVie and Bristol-Myers Squibb's daclatasvir, which has put up impressive results in trials, too, but works best when used alongside Sovaldi.

3. Biogen's Tecfidera
Drug distributor Express Scripts expects sales of specialty multiple sclerosis drugs will increase 12% per year through 2016, making it one of the fastest-growing specialty drug markets. That growth is due to a wave of new oral drugs designed to reduce MS relapses and replace prior-generation injectable therapies including Teva's $4-billion-a-year Copaxone.

The first oral competitor out of the gate was Novartis' (NYSE:NVS) Gilenya, a drug that outperformed Biogen's injectable Avonex in head-to-head trials. Gilenya's advantage over Avonex helped Novartis capture significant global market share as it launched overseas last year. As a result, Gilenya recorded first-quarter sales of $260 million in the U.S. and $292 million overseas.

However, Gilenya's pole position as the leading global oral MS therapy may be short-lived given Biogen's highly successful launch of Tecfidera. Since getting the FDA's go-ahead last spring, Tecfidera sales leaped to more than $300 million in the fourth quarter, bringing its 2013 sales to more than $875 million. That momentum carried over into the first quarter, with Tecfidera's sales totaling over $500 million. That gives it a $2 billion annualized run rate; however, its potential is likely to be far greater than that given it's only now beginning to ramp overseas.

So far, the vast majority of Tecfidera's sales have come from the U.S., but with the drug winning EU approval in January and price negotiations with EU member countries under way, overseas sales should steadily climb throughout this year.

Foolworthy final thoughts
A lot of the potential for these drugs may be priced into shares given their rapid rise in the past year. However, if these drugs end up outperforming as they roll out internationally and win label expansions, sales and profit growth may mean these companies could still head higher. That suggests investors should keep an eye out for opportuntiies to buy shares on sale, particularly if quarterly results continue to impress. 

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.

Todd Campbell owns shares of Gilead Sciences. He owns E.B. Capital Markets, LLC, whose clients may or may not have positions in the companies mentioned. He also owns Gundalow Advisors, LLC, whose clients do not have positions in the companies mentioned. The Motley Fool recommends Express Scripts, Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Express Scripts, Gilead Sciences, and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers